

# Chih-Lin Lin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7128786/publications.pdf>

Version: 2024-02-01

51  
papers

1,740  
citations

331259

21  
h-index

276539

41  
g-index

51  
all docs

51  
docs citations

51  
times ranked

2354  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1478-1487.	0.8	12
2	Impact of PNPLA3 p.I148M and Hepatic Steatosis on Long-Term Outcomes for Hepatocellular Carcinoma and HBsAg Seroclearance in Chronic Hepatitis B. <i>Journal of Hepatocellular Carcinoma</i> , 2022, Volume 9, 301-313.	1.8	11
3	Response to letter to the editor "Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy". <i>Journal of the Formosan Medical Association</i> , 2021, 120, 915-917.	0.8	0
4	Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection. , 2021, , 231-250.		1
5	Differentiation of clinical patterns and survival outcomes of hepatocellular carcinoma on hepatitis B and nonalcoholic fatty liver disease. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 606-613.	0.6	10
6	Superinfection of other hepatitis viruses on top of chronic hepatitis B: The more, the worse. <i>Advances in Digestive Medicine</i> , 2021, 8, 199-200.	0.1	0
7	Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1483-1489.	0.8	7
8	Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , 2020, 59, 1269-1279.	1.3	10
9	Hepatitis B. <i>Gastroenterology Clinics of North America</i> , 2020, 49, 201-214.	1.0	15
10	Smoking and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase. <i>Hepatology</i> , 2019, 69, 1412-1425.	3.6	26
11	Sigmoid colonic endometriosis mimicking colon cancer: A case report. <i>Advances in Digestive Medicine</i> , 2018, 5, 59-62.	0.1	1
12	Combination therapy for chronic hepatitis B: The future and beyond. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 745-746.	0.8	2
13	Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers. <i>Molecular Carcinogenesis</i> , 2017, 56, 425-435.	1.3	21
14	Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace. <i>Hepatology International</i> , 2017, 11, 31-33.	1.9	4
15	Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 249-255.	1.0	135
16	Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study. <i>Gastroenterology</i> , 2017, 153, 1006-1017.e5.	0.6	123
17	CYP2C19 polymorphism has no influence on rabeprazole-based sequential therapy. <i>Advances in Digestive Medicine</i> , 2017, 4, 134-139.	0.1	0
18	New perspectives of biomarkers for the management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 423-431.	4.5	52

#	ARTICLE	IF	CITATIONS
19	Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma. <i>Hepatology</i> , 2016, 64, 720-731.	3.6	13
20	Efficacy of entecavir therapy for hepatitis B e antigen positive chronic hepatitis B patients with prior exposure to interferon or nucleoside/nucleotide analogues. <i>Hepatology Research</i> , 2016, 46, 642-649.	1.8	1
21	Hepatitis B virus: new therapeutic perspectives. <i>Liver International</i> , 2016, 36, 85-92.	1.9	39
22	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. <i>Liver International</i> , 2016, 36, 1755-1764.	1.9	177
23	Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. <i>Hepatology International</i> , 2016, 10, 294-301.	1.9	3
24	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. <i>Scientific Reports</i> , 2015, 5, 11710.	1.6	7
25	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. <i>Scientific Reports</i> , 2015, 5, 15255.	1.6	8
26	Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B?. <i>Hepatology</i> , 2015, 62, 1924-1925.	3.6	1
27	Development of risk scoring system for stratifying population for hepatocellular carcinoma screening. <i>Hepatology</i> , 2015, 61, 1934-1944.	3.6	46
28	What can we learn from hepatitis B virus clinical cohorts?. <i>Liver International</i> , 2015, 35, 91-99.	1.9	12
29	Comparison of Abbott RealTime HCV Genotype II with Versant Line Probe Assay 2.0 for Hepatitis C Virus Genotyping. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1754-1757.	1.8	62
30	Hepatitis B Virus Genotypes and Variants. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021436-a021436.	2.9	188
31	Fibrosis index based on four factors better predicts advanced fibrosis or cirrhosis than aspartate aminotransferase/platelet ratio index in chronic hepatitis C patients. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 923-928.	0.8	29
32	Perspectives and control of hepatitis B virus infection in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 901-909.	0.8	63
33	HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. <i>Journal of the Formosan Medical Association</i> , 2015, 114, 308-313.	0.8	11
34	Circulating Programmed Death-1 as a Marker for Sustained High Hepatitis B Viral Load and Risk of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e95870.	1.1	64
35	Younger age and female sex predict a better therapeutic response in HBeAg-positive chronic hepatitis B patients to entecavir therapy. <i>Advances in Digestive Medicine</i> , 2014, 1, 112-117.	0.1	1
36	Risk factors for 1-year mortality in patients with intermediate-stage hepatocellular carcinoma treated solely with transcatheter arterial chemoembolization. <i>Advances in Digestive Medicine</i> , 2014, 1, 126-131.	0.1	3

#	ARTICLE	IF	CITATIONS
37	Hepatitis B Virus Genotypes: Clinical Relevance and Therapeutic Implications. <i>Current Hepatitis Reports</i> , 2013, 12, 124-132.	0.3	0
38	Risk stratification for hepatitis B virus related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 10-17.	1.4	82
39	Hepatitis B viral factors and treatment responses in chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2013, 112, 302-311.	0.8	39
40	Host genetic variants and hepatitis B virologic features in HBeAg-negative hepatitis B carriers with long-term biochemical remission. <i>Hepatology International</i> , 2012, 6, 598-605.	1.9	2
41	Recent advances in the treatment of chronic hepatitis B. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2025-2040.	0.9	26
42	Clinical Implications of Hepatitis B Virus Variants. <i>Journal of the Formosan Medical Association</i> , 2010, 109, 321-325.	0.8	8
43	Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. <i>Journal of Biomedical Science</i> , 2008, 15, 137-145.	2.6	97
44	Hepatitis B viral load as a prognostic factor for patients with unresectable hepatocellular carcinoma. <i>Future Virology</i> , 2007, 2, 441-443.	0.9	0
45	Hepatitis B viral factors in HBeAg-Negative carriers with persistently normal serum alanine aminotransferase levels. <i>Hepatology</i> , 2007, 45, 1193-1198.	3.6	103
46	Reply:. <i>Hepatology</i> , 2007, 46, 947-949.	3.6	3
47	High prevalence of occult hepatitis B virus infection in Taiwanese intravenous drug users. <i>Journal of Medical Virology</i> , 2007, 79, 1674-1678.	2.5	25
48	Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1098-1103.	1.4	76
49	Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. <i>Liver International</i> , 2005, 25, 564-570.	1.9	68
50	Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy. <i>Liver International</i> , 2004, 24, 9-15.	1.9	14
51	Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. <i>Journal of Gastroenterology</i> , 2002, 37, 283-287.	2.3	39